Genmab — Juni 2015
-
However, Dr Lentzsch believes that daratumumab will probably not be used as a single agent but as part of combination therapy. Daratumumab is currently being studied in several ongoing phase 3 trials that are exploring daratumumab in combination with various existing regimens in different stages of the disease.
"The next step is to establish efficacy in combination with other agents and to bring it to frontline therapy," she said.
-
Copenhagen, Denmark; June 2, 2015 – Genmab A/S (OMX: GEN) announced today that its CEO,
Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 36th Annual Global
Healthcare Conference in Rancho Palos Verdes, California at 4:00PM PDT on June 9, 2015 /
1:00AM CEST on June 10, 2015. A webcast of the presentation will be available on Genmab’s website -
Copenhagen, Denmark; May 21, 2015 — Genmab A/S (OMX: GEN) announced today that data on ofatumumab and daratumumab will be presented at the 20th Congress of the European Hematology Association (EHA) in Vienna, June 11-14. The abstracts have been published at the EHA website at www.ehaweb.org.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
